Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756051 · ClinicalTrials.gov registry record
Harms of Hepatocellular Carcinoma Surveillance
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 2,871
- Enrollment target
NCT03756051: Completed study, sponsored by University of Texas Southwestern Medical Center.
NCT03756051 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2,871 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03756051 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 2,871 participants
- Enrollment target
Study Summary
This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse population of patients with cirrhosis. However, the randomized controlled trial was not budgeted to assess hepatocellular carcinoma screening-related harms. The goal of this study is to quantify physical, financial, and psychosocial harms across three healthcare settings.
Primary Outcome
Physical harms (contrast injury, radiation exposure, and biopsy complications) can result from screening or follow-up testing and extends beyond medical complications to include discomfort. A binary outcome (harm vs. no harm) will be defined for each person and each type of physical harm (contrast injury, radiation exposure, biopsy, and any physical harm). We will report the point estimate and 95% confidence interval for the proportion of patients with each type of harm in each arm, stratified b
Interventions
- OTHER Prospective Longitudinal Data
- OTHER Surveys and Semi-structured Interviews
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,871 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2022-06-30 |
What the finished NCT03756051 record still lists
NCT03756051 is an observational study that tracks outcomes without assigning an intervention. Its 2,871 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Prospective Longitudinal Data is the first listed.
NCT03756051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03756051 about?
NCT03756051 is a clinical study titled "Harms of Hepatocellular Carcinoma Surveillance". This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse population of patients with cirrhosis. However, the randomized controlled trial...
What is the current status of trial NCT03756051?
This trial is currently completed. The enrollment target is 2,871 participants. The study started on 2018-04-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03756051?
The interventions under investigation include: Prospective Longitudinal Data (OTHER), Surveys and Semi-structured Interviews (OTHER).
Who is sponsoring clinical trial NCT03756051?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI